The Role Of Serds In The Treatment Landscape Of Patients With Er+/Her2- Breast Cancer

The role of SERDs in the treatment landscape of patients with ER+/HER2- breast cancer

Navigating the Expanding Treatment Arsenal for ER+/HER2- Breast Cancer

PeerView Oncology

What does the future hold for SERDs in ER+ breast cancer?

SERDs for patients with ER+/HER2- breast cancer

Expanding Treatment Options in ER+/HER2- Breast Cancer: SERDs, SERMs, SERCAs, and More

PeerView Oncology

ER-Positive Breast Cancer: What's New in Treatment and Research at MBC Patient Forum 2019

Dana-Farber Cancer Institute

The landscape of oral SERDs and their potential in ER+ breast cancer

SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Novel ER-Targeting Therapies

PeerView Oncology

Overview of Clinical Data of SERDs & Their Place in Treatment Landscape

COR2ED The Heart of Medical Education

Key trial updates in SERDs in ER+/HER2- breast cancer from SABCs 2022

The emerging role of SERD's in HR+ breast cancer

Touch Medical Media Services

Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Breast Cancer

COR2ED The Heart of Medical Education

Oral SERDS: New endocrine therapy options in ER+ metastatic breast cancer - a patient case video

COR2ED The Heart of Medical Education

Navigating ER+ metastatic breast cancer: Explore a patient case

COR2ED The Heart of Medical Education

Changing Treatment Landscape In HR+HER2 aBC

Kavina Creations

EMERALD: elacestrant vs physicians choice in ER+/HER2- breast cancer

Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance

Genomic and transcriptomic landscape of HER2-low breast cancer

Optimising Treatment Selection for Patients with ER+/HER2- Breast Cancer

COR2ED The Heart of Medical Education

Key challenge associated with the management of HR+/HER2- breast cancer